Cargando…

Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors

CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Yasunori, Kamitani, Fumika, Yamamoto, Masaaki, Fukuoka, Hidenori, Hirota, Yushi, Nishiyama, Nobuharu, Goda, Naho, Okada, Yuko, Inaba, Yuiko, Nakajima, Hiroki, Kurematsu, Yukako, Kanie, Keitaro, Shichi, Hiroki, Urai, Shin, Suzuki, Masaki, Yamamoto, Naoki, Bando, Hironori, Iguchi, Genzo, Suto, Hirotaka, Funakoshi, Yohei, Kiyota, Naomi, Takahashi, Yutaka, Ogawa, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856268/
https://www.ncbi.nlm.nih.gov/pubmed/36694808
http://dx.doi.org/10.1210/jendso/bvad002
_version_ 1784873578491019264
author Fujita, Yasunori
Kamitani, Fumika
Yamamoto, Masaaki
Fukuoka, Hidenori
Hirota, Yushi
Nishiyama, Nobuharu
Goda, Naho
Okada, Yuko
Inaba, Yuiko
Nakajima, Hiroki
Kurematsu, Yukako
Kanie, Keitaro
Shichi, Hiroki
Urai, Shin
Suzuki, Masaki
Yamamoto, Naoki
Bando, Hironori
Iguchi, Genzo
Suto, Hirotaka
Funakoshi, Yohei
Kiyota, Naomi
Takahashi, Yutaka
Ogawa, Wataru
author_facet Fujita, Yasunori
Kamitani, Fumika
Yamamoto, Masaaki
Fukuoka, Hidenori
Hirota, Yushi
Nishiyama, Nobuharu
Goda, Naho
Okada, Yuko
Inaba, Yuiko
Nakajima, Hiroki
Kurematsu, Yukako
Kanie, Keitaro
Shichi, Hiroki
Urai, Shin
Suzuki, Masaki
Yamamoto, Naoki
Bando, Hironori
Iguchi, Genzo
Suto, Hirotaka
Funakoshi, Yohei
Kiyota, Naomi
Takahashi, Yutaka
Ogawa, Wataru
author_sort Fujita, Yasunori
collection PubMed
description CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.
format Online
Article
Text
id pubmed-9856268
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98562682023-01-23 Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors Fujita, Yasunori Kamitani, Fumika Yamamoto, Masaaki Fukuoka, Hidenori Hirota, Yushi Nishiyama, Nobuharu Goda, Naho Okada, Yuko Inaba, Yuiko Nakajima, Hiroki Kurematsu, Yukako Kanie, Keitaro Shichi, Hiroki Urai, Shin Suzuki, Masaki Yamamoto, Naoki Bando, Hironori Iguchi, Genzo Suto, Hirotaka Funakoshi, Yohei Kiyota, Naomi Takahashi, Yutaka Ogawa, Wataru J Endocr Soc Clinical Research Article CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required. Oxford University Press 2023-01-06 /pmc/articles/PMC9856268/ /pubmed/36694808 http://dx.doi.org/10.1210/jendso/bvad002 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research Article
Fujita, Yasunori
Kamitani, Fumika
Yamamoto, Masaaki
Fukuoka, Hidenori
Hirota, Yushi
Nishiyama, Nobuharu
Goda, Naho
Okada, Yuko
Inaba, Yuiko
Nakajima, Hiroki
Kurematsu, Yukako
Kanie, Keitaro
Shichi, Hiroki
Urai, Shin
Suzuki, Masaki
Yamamoto, Naoki
Bando, Hironori
Iguchi, Genzo
Suto, Hirotaka
Funakoshi, Yohei
Kiyota, Naomi
Takahashi, Yutaka
Ogawa, Wataru
Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
title Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
title_full Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
title_fullStr Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
title_full_unstemmed Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
title_short Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
title_sort combined hypophysitis and type 1 diabetes mellitus related to immune checkpoint inhibitors
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856268/
https://www.ncbi.nlm.nih.gov/pubmed/36694808
http://dx.doi.org/10.1210/jendso/bvad002
work_keys_str_mv AT fujitayasunori combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT kamitanifumika combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT yamamotomasaaki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT fukuokahidenori combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT hirotayushi combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT nishiyamanobuharu combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT godanaho combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT okadayuko combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT inabayuiko combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT nakajimahiroki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT kurematsuyukako combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT kaniekeitaro combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT shichihiroki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT uraishin combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT suzukimasaki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT yamamotonaoki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT bandohironori combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT iguchigenzo combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT sutohirotaka combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT funakoshiyohei combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT kiyotanaomi combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT takahashiyutaka combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors
AT ogawawataru combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors